Rabbit Polyclonal CyclophilinD Antibody

+ +

•  

   
     All lanes : Anti-Cyclophilin D Antibody at  1:2000 dilution Lane 1: K562 whole cell lysate Lane 2: HepG2 whole cell lysate Lane 3: Jurkat whole cell lysate Lane 4: CCRF-CEM whole cell lysate Lane 5: human brain lysate Lysates/proteins at 20 µg per lane. Secondary Goat Anti-Rabbit IgG,  (H+L), Peroxidase conjugated at 1/10000 dilution. Predicted band size : 41 kDa Blocking/Dilution buffer: 5% NFDM/TBST.    

•  

   
     Immunofluorescent analysis of 4% paraformaldehyde-fixed, 0.1% Triton X-100 permeabilized HepG2 (human liver hepatocellular carcinoma cell line) cells labeling Cyclophilin D  with P34037 at 1/25 dilution, followed by Dylight® 488-conjugated goat anti-rabbit IgG  secondary antibody at 1/200 dilution (green). Immunofluorescence image showing cytoplasm staining on HepG2 cell line. The nuclear counter stain is DAPI (blue).    

•  

   
     Overlay histogram showing K562 cells stained with P34037 (green line).  The cells were fixed with 2% paraformaldehyde (10 min) and then permeabilized with 90% methanol for 10 min.  The cells were then icubated in 2% bovine serum albumin to block non-specific protein-protein interactions followed by the antibody (P34037,  1:25 dilution) for 60 min at 37ºC.  The secondary antibody used was Goat-Anti-Rabbit IgG, DyLight® 488 Conjugated Highly Cross-Adsorbed(OH191631) at 1/200 dilution for 40 min at 37ºC.  Isotype control antibody (blue line) was rabbit IgG (1μg/1x10^6 cells) used under the same conditions.  Acquisition of >10, 000 events was performed.    

•  

   
     P34037 staining Cyclophilin D in human brain tissue sections by Immunohistochemistry (IHC-P - paraformaldehyde-fixed,  paraffin-embedded sections).  Tissue was fixed with formaldehyde and blocked with 3% BSA for 0. 5 hour at room temperature; antigen retrieval was by heat mediation with a citrate buffer (pH6).  Samples were incubated with primary antibody (1/25) for 1 hours at 37°C.  A undiluted biotinylated goat polyvalent antibody was used as the secondary antibody.    

Cyclophilin D (CypD), encoded by the *PPIF* gene, is a mitochondrial matrix protein belonging to the immunophilin family. It acts as a peptidyl-prolyl isomerase, facilitating protein folding and modulating mitochondrial permeability transition pore (mPTP) opening—a critical event in apoptosis, necrosis, and ischemia-reperfusion injury. CypD’s interaction with the mPTP complex regulates calcium homeostasis, oxidative stress responses, and cell death pathways, making it a key player in neurodegenerative diseases, cardiovascular disorders, and cancer.

Antibodies targeting CypD are essential tools for studying its expression, localization, and function in cellular and disease models. They are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to assess CypD levels in tissues or cells under stress, metabolic alterations, or drug treatment. Specificity is crucial, as CypD shares structural homology with other cyclophilin family members. High-quality antibodies help validate CypD’s role in mitochondrial dysfunction and evaluate therapeutic strategies targeting mPTP inhibition (e.g., cyclosporine A). Research using CypD antibodies has advanced understanding of its dual roles in promoting cell death during injury while supporting survival in certain cancers, highlighting its context-dependent therapeutic potential.